Emerald Mutual Fund Advisers Trust lessened its holdings in shares of KalVista Pharmaceuticals, Inc. (NASDAQ:KALV – Free Report) by 5.8% in the first quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 805,762 shares of the specialty pharmaceutical company’s stock after selling 49,699 shares during the quarter. Emerald Mutual Fund Advisers Trust’s holdings in KalVista Pharmaceuticals were worth $16,220,000 as of its most recent SEC filing.
Several other institutional investors have also recently bought and sold shares of KALV. Vanguard Group Inc. lifted its stake in shares of KalVista Pharmaceuticals by 3.7% in the third quarter. Vanguard Group Inc. now owns 2,501,119 shares of the specialty pharmaceutical company’s stock valued at $30,464,000 after buying an additional 88,720 shares in the last quarter. Tudor Investment Corp ET AL bought a new stake in shares of KalVista Pharmaceuticals during the third quarter worth about $24,360,000. State Street Corp increased its position in shares of KalVista Pharmaceuticals by 21.3% during the fourth quarter. State Street Corp now owns 1,911,691 shares of the specialty pharmaceutical company’s stock worth $30,874,000 after acquiring an additional 336,195 shares in the last quarter. Vestal Point Capital LP raised its holdings in shares of KalVista Pharmaceuticals by 152.0% in the 4th quarter. Vestal Point Capital LP now owns 1,890,000 shares of the specialty pharmaceutical company’s stock worth $30,524,000 after acquiring an additional 1,140,000 shares during the last quarter. Finally, Parkman Healthcare Partners LLC raised its holdings in shares of KalVista Pharmaceuticals by 155.5% in the 3rd quarter. Parkman Healthcare Partners LLC now owns 1,735,003 shares of the specialty pharmaceutical company’s stock worth $21,132,000 after acquiring an additional 1,055,940 shares during the last quarter.
Analysts Set New Price Targets
Several equities analysts recently weighed in on KALV shares. HC Wainwright cut shares of KalVista Pharmaceuticals from a “buy” rating to a “neutral” rating and dropped their price target for the company from $37.00 to $27.00 in a research report on Friday, May 1st. Citizens Jmp downgraded KalVista Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a research note on Wednesday, April 29th. Leerink Partners lowered KalVista Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a report on Wednesday, April 29th. JonesTrading lowered KalVista Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a report on Thursday, April 30th. Finally, Needham & Company LLC cut KalVista Pharmaceuticals from a “buy” rating to a “hold” rating in a research report on Thursday, April 30th. Three research analysts have rated the stock with a Buy rating, five have issued a Hold rating and one has given a Sell rating to the company. According to MarketBeat.com, the company presently has an average rating of “Hold” and an average price target of $33.25.
KalVista Pharmaceuticals Price Performance
KALV opened at $27.00 on Tuesday. The company has a debt-to-equity ratio of 8.18, a current ratio of 5.17 and a quick ratio of 5.10. The company’s 50-day moving average is $26.90 and its 200 day moving average is $20.54. KalVista Pharmaceuticals, Inc. has a fifty-two week low of $9.83 and a fifty-two week high of $27.00. The firm has a market capitalization of $1.44 billion, a P/E ratio of -7.80 and a beta of -0.12.
KalVista Pharmaceuticals (NASDAQ:KALV – Get Free Report) last released its quarterly earnings results on Thursday, May 14th. The specialty pharmaceutical company reported ($0.43) earnings per share for the quarter, missing the consensus estimate of ($0.38) by ($0.05). The company had revenue of $40.86 million for the quarter, compared to analyst estimates of $39.03 million. Research analysts expect that KalVista Pharmaceuticals, Inc. will post -1.19 earnings per share for the current fiscal year.
Insider Activity
In other news, CEO Benjamin L. Palleiko sold 10,926 shares of the business’s stock in a transaction that occurred on Friday, May 22nd. The stock was sold at an average price of $26.78, for a total value of $292,598.28. Following the transaction, the chief executive officer owned 479,989 shares in the company, valued at $12,854,105.42. The trade was a 2.23% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, CFO Brian Piekos sold 1,862 shares of the company’s stock in a transaction that occurred on Friday, April 17th. The shares were sold at an average price of $20.22, for a total value of $37,649.64. Following the completion of the transaction, the chief financial officer directly owned 18,150 shares of the company’s stock, valued at approximately $366,993. This represents a 9.30% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Insiders sold 39,971 shares of company stock worth $965,493 in the last quarter. 4.30% of the stock is owned by corporate insiders.
KalVista Pharmaceuticals Profile
KalVista Pharmaceuticals is a clinical‐stage biotechnology company focused on the discovery and development of small‐molecule protease inhibitors for orphan and specialty disease indications. The firm’s scientific platform centers on selective inhibition of plasma kallikrein, a serine protease implicated in disorders characterized by vascular leak, edema and inflammation. KalVista’s approach leverages oral and intravitreal delivery formats to target both systemic and ophthalmic conditions.
The company’s lead programs include an oral plasma kallikrein inhibitor in clinical trials for the acute treatment of hereditary angioedema (HAE) attacks and an intravitreal kallikrein inhibitor being evaluated for diabetic macular edema.
Featured Stories
- Five stocks we like better than KalVista Pharmaceuticals
- The SK Hynix IPO and 2027’s AI Memory Squeeze
- Meta Platforms Stock Rises as Muse Spark 1.1 AI Model Debuts
- Why Welltower’s Growth Story Might Outrun Its Rich Valuation
- One Short- and One Long-Term ETF for Quantum Computing Bulls
Want to see what other hedge funds are holding KALV? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for KalVista Pharmaceuticals, Inc. (NASDAQ:KALV – Free Report).
Receive News & Ratings for KalVista Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for KalVista Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.
